Recent progress concerning CpG DNA and its use as a vaccine adjuvant

Hidekazu Shirota, Dennis M. Klinman

Research output: Contribution to journalReview articlepeer-review

123 Citations (Scopus)


CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides designed to specifically agonize Toll-like receptor 9. Here, we review recent progress in understanding the mechanism of action of CpG ODN and provide an overview of human clinical trial results using CpG ODN to improve the vaccines for cancer, allergy and infectious disease.

Original languageEnglish
Pages (from-to)299-312
Number of pages14
JournalExpert Review of Vaccines
Issue number2
Publication statusPublished - 2014 Feb


  • CpG oligonucleotide
  • Toll-like receptor
  • allergy
  • cancer
  • infection
  • vaccine adjuvant

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Recent progress concerning CpG DNA and its use as a vaccine adjuvant'. Together they form a unique fingerprint.

Cite this